eXoZymes raised approximately $0.64 million in gross proceeds through a registered offering of 35,555 units at $18.00 per unit, each consisting of one share and one warrant. Net proceeds, after $44,799 in commissions and about $30,000 in expenses, will support NCT technology development, next-in-line products, R&D, and general corporate purposes. The company entered a Placement Agent Agreement with MDB Capital, executed an investor Securities Purchase Agreement, and modified its Warrant Agent Agreement with VStock Transfer to cover the newly issued warrants. The warrants carry a $11.24 exercise price, become exercisable on Jun 5, 2027, and expire on Jun 5, 2031, with a reset feature under specified pre-commencement financings.
Agreement 1: eXoZymes Raises $0.64 Million in Unit Offering; MDB Capital Acts as Placement Agent
- Agreement type: Placement Agent Agreement for registered direct unit offering
- Counterparty: MDB Capital
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: Transaction-specific
- Reason: Raise capital for NCT development and corporate purposes
Agreement 2: eXoZymes Enters Securities Purchase Agreement for 35,555 Units Priced at $18.00
- Agreement type: Securities purchase agreement for registered unit offering
- Counterparty: An investor
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: Transaction-specific
- Reason: Provide equity funding for NCT initiatives and operations
Agreement 3: eXoZymes Modifies Warrant Agent Pact With VStock Transfer to Cover New Warrants
- Agreement type: Modification to Warrant Agent Agreement
- Counterparty: VStock Transfer
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: Through Jun 05 2031
- Reason: Administer warrants issued in the offering
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.